Immucell Corp /De/ (ICCC) — SEC Filings
Immucell Corp /De/ (ICCC) — 36 SEC filings. Latest: 8-K (Dec 29, 2025). Includes 26 8-K, 5 10-Q, 2 DEF 14A.
View Immucell Corp /De/ on SEC EDGAR
Overview
Immucell Corp /De/ (ICCC) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 29, 2025: ImmuCell Corporation filed an 8-K on December 29, 2025, reporting events that occurred on December 24, 2025. The filing indicates items related to material impairments, other events, and financial statements and exhibits.
Sentiment Summary
Across 36 filings, the sentiment breakdown is: 1 bullish, 35 neutral. The dominant filing sentiment for Immucell Corp /De/ is neutral.
Filing Type Overview
Immucell Corp /De/ (ICCC) has filed 26 8-K, 5 10-Q, 2 DEF 14A, 2 10-K, 1 SC 13D with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (36)
Risk Profile
Risk Assessment: Of ICCC's 35 recent filings, 0 were flagged as high-risk, 16 as medium-risk, and 19 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $14,512,054 |
| Net Income | $1,948,863 |
| EPS | $0.22 |
| Debt-to-Equity | 0.56 |
| Cash Position | $5,998,494 |
| Operating Margin | 11.63% |
| Total Assets | $46,720,898 |
| Total Debt | $9,798,662 |
Key Executives
- Dr. Michael J. McGeary
- Dr. Robert J. Barchi
- Mr. David M. Smith
- Ejnar A. Knudsen III
Industry Context
ImmuCell operates in the animal health sector, focusing on novel biologics for livestock. The industry is characterized by increasing demand for animal welfare and productivity, driving innovation in disease prevention and treatment. Key trends include the development of targeted therapies and the need for regulatory compliance for new animal drugs.
Top Tags
8-K (7) · financial-reporting (7) · 8-k (6) · material-agreement (6) · sec-filing (5) · results-of-operations (4) · financial-obligation (3) · 10-Q (3) · operations (3) · financial-condition (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| SEC File Number | 001-12934 | Identifies the company's filing with the SEC. |
| IRS Employer Identification No. | 01-0382980 | Company's tax identification number. |
| Net Income | $1.95M | Swung from a $1.97M net loss in the prior six-month period to a $1.95M net income for the six months ended June 30, 2025. |
| Product Sales | $14.51M | Increased by 14% from $12.73M in the prior six-month period to $14.51M for the six months ended June 30, 2025. |
| Gross Margin | $6.17M | More than doubled from $3.53M in the prior six-month period to $6.17M for the six months ended June 30, 2025. |
| Cash and Cash Equivalents | $5.99M | Increased by $2.24M from $3.76M at December 31, 2024, to $5.99M as of June 30, 2025. |
| Basic Net Income Per Share | $0.22 | Improved from a loss of $0.25 per share in the prior six-month period to an income of $0.22 per share for the six months ended June 30, 2025. |
| Re-Tain Assets | $25.26M | Represents the total investment in land, buildings, and equipment for the Re-Tain project as of June 30, 2025. |
| Filing Date | 20250424 | Date the definitive proxy statement was filed with the SEC. |
| Meeting Date | 20250612 | Date of the shareholder meeting for which this proxy statement is issued. |
| IRS Number | 01-0382980 | Company's Employer Identification Number. |
| Shares Outstanding | 7,811,874 | As of May 3, 2024 |
| Quarterly Period End Date | 2024-03-31 | For the quarterly period ended |
| Annual Meeting Date | June 13, 2024 | Date of the Annual Meeting of Stockholders |
| Meeting Time | 9:30 AM ET | Time of the Annual Meeting of Stockholders |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Immucell Corp /De/ (ICCC)?
Immucell Corp /De/ has 36 recent SEC filings from Jan 2024 to Dec 2025, including 26 8-K, 5 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ICCC filings?
Across 36 filings, the sentiment breakdown is: 1 bullish, 35 neutral. The dominant sentiment is neutral.
Where can I find Immucell Corp /De/ SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Immucell Corp /De/ (ICCC) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Immucell Corp /De/?
Key financial highlights from Immucell Corp /De/'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ICCC?
The investment thesis for ICCC includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Immucell Corp /De/?
Key executives identified across Immucell Corp /De/'s filings include Dr. Michael J. McGeary, Dr. Robert J. Barchi, Mr. David M. Smith, Ejnar A. Knudsen III.
What are the main risk factors for Immucell Corp /De/ stock?
Of ICCC's 35 assessed filings, 0 were flagged high-risk, 16 medium-risk, and 19 low-risk.
What are recent predictions and forward guidance from Immucell Corp /De/?
Forward guidance and predictions for Immucell Corp /De/ are extracted from SEC filings as they are enriched.